Clinical Trial Update: Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AVE5026 to prevent venous thromboembolism in cancer patients undergoing chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Venous Thromboembolism

Drugs mentioned

• AVE5026

Snippet

Sponsor: Sanofi | Conditions: Venous Thromboembolism, Cancer | Phase 3 | Status: COMPLETED